[Novo Nordisk’s marketing application for new weight management drug Cagrilintide and Semaglutide Injection (CagriSema) has been accepted by the State Food and Drug Administration] On November 10, Novo Nordisk announced that its marketing application for its new drug Cagrilintide and Semaglutide Injection (CagriSema) for long-term weight management has been accepted by the State Food and Drug Administration. The drug is a fixed-dose combination preparation, consisting of the long-acting amylin receptor agonist carrelintide and the GLP-1 receptor agonist semaglutide, and is injected subcutaneously once a week. These two ingredients work together through different and complementary mechanisms of action on pathways related to appetite and weight regulation. (Interface News reporter Chen Yang)